Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Momenta Pharmaceuticals Inc. -- Ignore unavailable to you. Want to Upgrade?

To: IRWIN JAMES FRANKEL who wrote (956)	4/17/2007 8:07:52 PM
From: DewDiligence_on_SI	Read Replies (1) \| Respond to of 3027

TEVA would almost certainly not PR negative news from the FDA about generic Lovenox, IMO.

To: IRWIN JAMES FRANKEL who wrote (956)	9/30/2008 7:19:39 PM
From: DewDiligence_on_SI	Respond to of 3027

This discussion from 18 months ago (!) seems to be relevant to a recent thread: What if Amphastar has been told by the FDA that they are not going to be approved? Since it is a private company they would not have to announce it. Amphastar has to tell partner WPI what is going on with the Lovenox ANDA; investors can (and do) obtain a status update by asking about Lovenox during WPI’s CC’s. Would that info be insider info so as to prohibit trading on it? Just guessing but I think not. It would not be an SEC violation for insiders at Amphastar or WPI to trade MNTA shares using knowledge about Amphastar’s own ANDA. It might be contrary to these companies’ internal policies, however.